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Abstract 20 
Flupirtine (FLU) is a non-opioid analgesic drug with no antipyretic or antiphlogistic effects, 21 
used in the treatment of a wide range of pain states in human beings. There is a substantial body of 22 
evidence on the efficacy of FLU in humans but this is inadequate to recommend its off-label use in 23 
veterinary clinical practice. The aim of this study was to evaluate the pharmacokinetic profiles of 24 
FLU after IV and PO administration in healthy cats.  25 
 26 
Six mixed breed adult cats were randomly assigned to two treatment groups using an open, 27 
single-dose, two-treatment, two-phase, paired, cross-over design (2 x 2 Latin-square). Group 1 (n = 28 
3) received a single dose of 5 mg/kg of FLU injected IV into the jugular vein. Group 2 (n = 3) 29 
received the same dose via PO route. The wash out period was 1 week. Blood samples (1 mL) were 30 
collected at assigned times and plasma was then analysed by a validated HPLC method.  31 
 32 
No adverse effects at the point of injection and no behavioural changes or alterations in health 33 
parameters were observed in the animals during or after the study (up to 7 days after the full study). 34 
After IV administration, FLU was detectable in plasma up to 36 h. After PO administration, FLU 35 
plasma concentrations were lower than those following IV administration, but they were detectable 36 
over the same time range. The terminal part of both mean pharmacokinetic curves showed a similar 37 
trend of elimination. The oral bioavailability was approximately 40%. This is the first study of FLU 38 
in an animal species of veterinary interest and it could pave the way for the use of this active 39 
ingredient in the veterinary field. 40 
 41 
Keywords: Cats; Flupirtine; Intravenous; Oral; Pain reliever; Pharmacokinetics 42 
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Introduction 44 
Increasing numbers of animal species, especially those commonly kept as pets, are treated as 45 
members of the family and pet owners demand the same level of care they expect for themselves. 46 
This change in attitude has resulted in the increased development of more effective and innovative 47 
veterinary therapies (Giorgi, 2012; Giorgi and Yun, 2012). 48 
 49 
Pain management is a steadily emerging concept in veterinary medicine (Lamont, 2008) that 50 
has resulted in increased interest in the development of new techniques for pain management 51 
(Giorgi and Owen, 2012b; Giorgi et al., 2012). There is a limited number of analgesics licensed for 52 
cats, and off-label drug use is commonly practiced (Pypendop and Ilkiw, 2008; Lee et al, 2013). 53 
Recent investigations have shown that analgesic drugs are still under-used in feline medicine 54 
(Taylor, 2003) for fear of their associated side effects (Robertson and Taylor, 2004) It is therefore 55 
critical to investigate new active compounds to increase the drug armamentarium for use in cats. 56 
 57 
Flupirtine (FLU) is an aminopyridine drug (ethyl {2-amino-6-[(4-58 
fluorobenzyl)amino]pyridin- 3-yl}carbamate) that was approved in Europe in 1984 for the 59 
treatment of pain (Kumar et al., 2013) (Fig. 1). FLU is a centrally acting analgesic with a 60 
mechanism of action unlike that of opiates. It is active with a favourable tolerability and with no 61 
antipyretic or antiphlogistic effects (Singal et al., 2012). FLU is the first drug to be recognised in the 62 
unique  class  of  ‘selective  neuronal  potassium  channel  openers’  (SNEPCOs) (Kornhuber et al., 63 
1999). It interacts with the G-protein-regulated, inwardly rectifying K+ channels (GIRKs), a novel 64 
family of K+ channels distinct from the voltage-dependent ones. They are regulated by 65 
neurotransmitters and are expressed in different parts of the brain. FLU activates GIRKs and 66 
stabilizes the membrane resting potential by activating potassium channels KCNQ and thus 67 
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generating a neuronal hyperpolarizing current (M-current). The increased M-current due to the 68 
action of FLU translates to decreased neuronal excitability (Kolosov et al., 2012). Moreover, FLU 69 
inhibits the NMDA receptor indirectly by acting as an oxidizing agent at the redox site of the 70 
NMDA receptor, maintaining the Mg2+ block on the NMDA receptor (Singal et al., 2012). 71 
 72 
FLU can be useful in the treatment of a wide range of pain states in human beings. In line 73 
with its mechanism of action promoting neuronal rest, it has proved useful in conditions involving 74 
neuronal hyperexcitability such as chronic pain (non-malignant and malignant), migraine and 75 
neurogenic pain (Luben et al., 1994; Worz et al., 1996; Mueller-Schwefe, 2003; Ringe et al., 2003; 76 
Li et al., 2008; Szelenyi, 2013). Furthermore, its effect as a muscle relaxant represents added value 77 
in painful conditions associated with increased muscle tension, such as musculoskeletal back pain, 78 
myofascial pain and tension headaches (Worz, 1991; Worz et al., 1995; Worz et al., 1996; Banerjee 79 
et al., 2012; Kumar et al., 2013). FLU has also been shown as beneficial in the short-term treatment 80 
of acute to moderate pain such as postoperative pain, trauma and dysmenorrhoea (Heusinger, 1987).  81 
 82 
The approved indications of FLU differ between countries but mainly include the clinical 83 
management of musculoskeletal pain, postoperative pain, headache, dysmenorrhoea, neuralgia and 84 
neuritis, post-traumatic pain (trauma and chemical burns) and pain associated with cancer 85 
(Devulder, 2010; Harish et al., 2012). It was probably not used to its full potential as an analgesic in 86 
the first decade of the 21st century, but in recent years, there has been a resurgence in FLU use after 87 
discovery of its powerful-additive effects when used with opioids (Goodchild et al., 2008; Capuano 88 
et al., 2011; Kolosov et al., 2012) in addition to its properties when used alone (Wilhelmi, 2013).  89 
 90 
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While there is a substantial body of evidence on the efficacy of FLU in humans, the only 91 
study on the analgesic effect of FLU in animals in the literature looked at laboratory species 92 
(Gordon et al., 1987). However this is inadequate to recommend its off-label use in veterinary 93 
clinical practice (Giorgi and Owen, 2012a). The aim of this study was to evaluate the 94 
pharmacokinetic profiles of FLU after IV and PO administration in healthy cats.  95 
 96 
Materials and methods 97 
Chemical and reagents 98 
Pure FLU maleate salt and the internal standard trazodone (IS) powders (both >99.0% purity) 99 
were supplied by Sigma-Aldrich. HPLC grade acetonitrile (ACN), methanol (MeOH), 100 
dichloromethane (CH2Cl2) and ethyl acetate (AcOEt) were purchased from Merck. Ammonium 101 
acetate (AcONH4) was purchased from Carlo Erba. Deionised water was produced by a Milli-Q 102 
Milli-pore Water System, and all other reagents and materials were of analytical grade and supplied 103 
from commercial sources. The liquid chromatography (LC) mobile phase was filtered through 0.2 104 
µm cellulose acetate membrane filters (Sartorius Stedim Biotech) with a solvent filtration apparatus. 105 
 106 
Animal and experimental design 107 
Six mixed breed adult intact cats, three males and three females, aged between 3-6 years, with 108 
a bodyweight in the range 2.9-5.2 kg, were enrolled in the study. The cats were determined to be 109 
clinically healthy on physical examination, serum chemistry and haematological analyses. Animals 110 
were evaluated daily (for 1 week) for visible adverse effects by specialized personnel. Animal care 111 
and handling was performed according to the provision of the EC council Directive 86/609 EEC 112 
and also according to Institutional Animal Care and Use directives issued by the Animal Welfare 113 
Committee of the University of Lublin, which approved the study protocol. 114 
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 115 
Cats were randomly assigned to two treatment groups (six slips of paper marked with the 116 
numbers 1 to 6 in a box), using an open, single-dose, two-treatment, two-phase, paired, cross-over 117 
design (2x2 Latin-square). All cats were fasted for 12 h overnight before each experiment. During 118 
the first phase each cat in group 1 (n = 3) received a single dose of 5 mg/kg of FLU (Katadolon 100 119 
mg/3 mL vials, FLU D-gluconate AWD Pharma) injected IV into the jugular vein. Group 2 (n = 3) 120 
received the same dose via the PO route (Efiret 100 mg hard capsules, FLU maleate, Meda 121 
Pharma). A 1 week wash out period was observed between the phases, then the groups were rotated 122 
and the experiment was repeated.  123 
 124 
The right cephalic vein was catheterised to facilitate blood sampling. Blood samples (1 mL) 125 
were collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 24, 36 and 48 h after administration of FLU 126 
and placed in collection tubes containing lithium heparin. Samples were immediately centrifuged at 127 
2000 g (10 min), and the harvested plasma was stored at -20 °C until use within 30 days from 128 
collection.  129 
 130 
High performance liquid chromatography  131 
The analytical method was based on a previous method validated in dog plasma (De Vito et 132 
al., 2014). In brief, the high performance liquid chromatography (HPLC) system was an LC Jasco 133 
consisting of quaternary gradient system (PU 980) and an in line multilambda fluorescence detector 134 
(FP 1520). The chromatographic separation assay was performed with a Luna C18(2) analytical 135 
column (250 mm × 4.6 mm inner diameter, 5 µ particle size [Phenomenex]) preceded by a security 136 
guard column with the same stationary phase (C18(2) [Phenomenex]). The system was maintained at 137 
25 ºC. The mobile phase consisted of ACN:AcONH4 (20 mM) solution, pH 6.8 (60:40, v/v) at a 138 
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flow rate of 1 mL/min. Excitation and emission wavelengths were set at 323 and 370 nm, 139 
respectively. The elution of the substances was carried out in isocratic mode. 140 
 141 
Sample extraction 142 
The procedure was performed in a 15 mL polypropylene vial. A 500 μL aliquot of plasma was 143 
added to 100 μL of IS (100 μg/mL) and vortexed for 60 s. Four millilitres of AcOEt:CH2Cl2 (7:3 144 
v/v) were added, then the sample was vortexed (30 s), shaken (100 osc/min, 10 min) and 145 
centrifuged at 3000 g for 10 min at 10 °C. Three millilitres of the supernatant were collected in a 146 
separate vial. The organic phase was evaporated under a gentle stream of nitrogen at 40 °C and 147 
reconstituted with 500 μL of the mobile phase. Twenty microlitres of this latter solution were 148 
injected onto the HPLC-FL. 149 
 150 
Pharmacokinetic evaluation 151 
FLU plasma concentration vs. time curves were modelled for each subject using a mono- or a 152 
two-compartment open model (Gibaldi and Perrier, 1982). Comparison between competing models 153 
was  made  using  the  residual  plots,  visual  inspection  of  the  goodness  of  fit  curves  and  the  Akaike’s  154 
information criterion. A weighting (1/[actual plasma concentration]2) was used. The 155 
pharmacokinetic calculations were carried out using WinNonLin v 5.3 (Pharsight). The PO 156 
bioavailability was calculated from the ratio of the areas under the plasma FLU concentration curve 157 
after PO and IV administration, respectively, indexed to their respective dose: 158 
 159 
F (%) = AUCPO/AUCIV X 100 160 
 161 
Statistical analysis 162 
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Pharmacokinetic variables were  evaluated  using  Student’s  t test to determine statistically 163 
significant differences between the treatment groups and the gender. Both pharmacokinetic 164 
parameters and FLU plasma concentrations are presented as means ± standard deviation (normality 165 
tested by Shapiro-Wilk test). All analyses were conducted using GraphPad InStat (GraphPad 166 
Software). In all experiments, differences were considered significant if P < 0.05. 167 
 168 
Results 169 
The HPLC method was re-validated using cat plasma. Briefly, FLU was linear (r2 >0.99) in 170 
the range 10-2000 ng/mL. When samples exceeded the upper limit of the range, they were re-171 
analysed after appropriate dilution. The intraday repeatability was measured as coefficient of 172 
variation and was < 6.1%, whereas accuracy, measured as closeness to the concentration added on 173 
the same replicates, was < 5.9%.  174 
 175 
No adverse effects were noted at the point of injection and no behavioural changes or 176 
alterations in health parameters were observed in the animals during or (up to 7 days) after the 177 
study. Physiological signs and parameters were normal. 178 
 179 
A bi-compartmental model best fitted the plasma concentrations after IV and PO 180 
administrations in all the six cats. Two-compartment with bolus input and first-order output, were 181 
the micro-constants used as primary parameters for the IV administration while a first-order input, 182 
first-order output, no lag time and micro-constants as primary parameters was used for the PO 183 
administration. The average plasma concentration vs. time curves after both the administrations are 184 
shown in Fig. 2.  185 
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 186 
After IV administration, the FLU plasma concentration varied widely, especially in the initial 187 
samples. FLU was detectable in plasma up to 36 h, then at 48 h, the drug concentrations dropped 188 
down the LOQ of the method. After oral administration, the FLU plasma concentrations were lower 189 
than after IV administration, but were detectable over the same range of time. The Cmax (2460 190 
ng/mL) was shown at a Tmax of 2.78 h. The oral bioavailability (F%) was 39.3 ± 9.7%. The half-life 191 
of elimination (Beta_HL) values were similar for both routes. The terminal phase of both mean 192 
pharmacokinetic curves showed a similar trend of elimination. The mean values of both clearance 193 
(CL) and volume of distribution (V2) were significantly different between the groups. The complete 194 
pharmacokinetic parameters are reported in Table 1. No statistical differences in pharmacokinetics 195 
were found between the genders (P = 0.12).  196 
 197 
Discussion 198 
FLU is a centrally acting, non-opioid analgesic that is available in a number of European 199 
countries for the treatment of a variety of pain states (Devulder, 2010). The therapeutic benefits 200 
seen with FLU relate to its unique pharmacological properties. Recently its potential for use in 201 
veterinary medicine has been explored (Giorgi and Owen, 2012a). Preclinical studies showed that 202 
FLU was more potent than paracetamol and as potent as pentazocine in an electrostimulated pain 203 
test in mice (Nickel, 1987). FLU significantly prolonged the latency of the tail-flick test in rats 204 
(Szelenyi et al., 1989) and produced an efficacy profile superior to that of tramadol for cancer-205 
associated pain (Luben et al., 1994; Kolosov, 2012). FLU produced a significant increase in 206 
morphine antinociception when the two drugs were administered in combination in different rat 207 
models of pain (Goodchild et al., 2008; Capuano 2011). If the sparing opioid effect is also evident 208 
in cats, this active ingredient could play an important role in combinatorial analgesic therapy in 209 
order to avoid moderately high regimens of opioids. FLU might be also an attractive alternative for 210 
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patients with a history of adverse drug reaction to NSAIDs (Papich, 2008). Indeed it does not 211 
induce the gastrointestinal side effects evoked by classical NSAIDs or the cardio-/cerebrovascular 212 
and renal side effects evoked with chronic therapy with COX-2 selective inhibitors (Treudler et al., 213 
2011).  214 
 215 
The dose administered in the present study (5 mg/kg) was about three times higher than the 216 
minimum reported in human clinical practice (100 mg/subject). However, it was still within the 217 
recommended human clinical range (100-400 mg/subject/day) (Devulder, 2010). The rationale for 218 
dose selection of 5 mg/kg was that the ED50 of FLU after oral administration in the electrical tooth 219 
pulp stimulation test in dogs and cats was 3.5 mg/kg (Nickel, 1987) and 3 mg/kg (Gordon et al., 220 
1987), respectively. Moreover, FLU at 5 mg/kg in combinational therapy with morphine, increased 221 
the antinociceptive activity of morphine 4-fold without increasing the adverse effects (Goodchild et 222 
al., 2008; Capuano et al., 2011). No side effects were reported in these studies. The 5 mg/kg dose 223 
did not produce any visible side effect in the cats in the current study (for 7 days), a finding that 224 
supports the good safety profile of FLU in humans (Friedel and Fitton, 1993). It has been reported 225 
that FLU maintains glutathione levels, a property that has prevented cell death in human retinal 226 
pigmented epithelial cells (Wood et al., 1998). This feature could be exploited in animal species that 227 
only have small amounts of this enzyme, such as cats.  228 
 229 
FLU is a water soluble compound in the form of maleate salt (pKa 5.3) that is rapidly 230 
absorbed from the human gastro intestinal tract (Klawe and Maschke, 2009). The Tmax reported for 231 
humans (range 1.6-1.8 h) is a bit shorter than that found in this study (2.78 h). This difference could 232 
be attributed to a number of potential reasons including the large variation in this parameter in the 233 
cat, different efficacy of absorption or other species-specific factors. In contrast, the FLU plasma 234 
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maximal concentrations after PO route in humans (100 mg/subject) and in cats (5 mg/kg) were 235 
comparable if normalized for the administered dose (770 ng/mL vs. 2460 ng/mL) (Abrams et al., 236 
1988). A large difference between humans and cats has been shown in oral F%. This value was 237 
more than two times lower in cats than in humans (39.3% vs. 90%) (Hlavica and Niebch, 1985).  238 
 239 
Large differences in F% between humans and pets have previously been demonstrated, 240 
indicating that F% values derived in pets may be inapplicable to human and vice versa (Chiou et al., 241 
2000). Values of apparent CL and V2 after PO administration even after their normalization for F%, 242 
were different from those after IV administration suggesting that other phenomena such as the 243 
different pharmaceutical composition used in the IV and PO routes (D-gluconate vs. maleate, 244 
respectively) or a saturation of the metabolic enzymes (triggered by the high drug concentrations in 245 
the IV group), might have generated these differences. 246 
 247 
Although FLU has been used in the treatment of acute and chronic states in humans for 25 248 
years, no minimal effective concentration for pain relief has been reported yet. However, it is 249 
noteworthy that in cats (despite the low oral F%) a dose of 5 mg/kg PO produced FLU plasma 250 
concentrations higher that the plasma concentrations produced by the PO clinical dose (100 251 
mg/subject) reported in humans (Hlavica and Niebch, 1985).  252 
 253 
Following PO administration of FLU 100 mg, the mean terminal plasma elimination half-life 254 
was about 6.5 h in healthy humans (Abram et al., 1988), whereas it was about twice this time in cats 255 
(13.6 h). This is in line with the reduced clearance in cats compared to humans (Abram et al., 1988). 256 
A likely explanation for the long half-life shown in cats, is that while FLU is bio-transformed in the 257 
N-acetylated analogue D13223 in humans (Methling et al., 2009) the transformation could be 258 
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slower or may not occur in cats. Indeed, cats lack one of the two N-acetyl-transferases enzymes (the 259 
NAT2) normally expressed in humans (Trepanier et al., 1998 responsible for the D13223 metabolite 260 
formation.  261 
 262 
FLU is predominantly excreted in urine (about 72% in humans; Hlavica and Niebch, 1985). 263 
Although the CL value of FLU did not significantly change in patients with mild renal impairment 264 
compared to healthy patients, the half-life almost doubled (Abrams et al., 1988). Hence caution 265 
should be used in cats with presumed renal impairment. It has also been proven that old age is 266 
associated with increased half-life of the drug in humans (Abrams et al., 1988) and this should be 267 
taken into consideration if FLU is to be administered to elderly cats. 268 
 269 
Conclusion 270 
This is the first study on FLU in a species of veterinary interest. The pharmacokinetic profiles 271 
of FLU in the cat were somewhat different compared to the FLU disposition in humans. Although 272 
the PO F% of FLU was quite low, a 5 mg/kg administration gave plasma concentrations exceeding 273 
those reported in humans after clinical dosing. This study could pave the way for the use of this 274 
active drug in the veterinary field.  275 
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Table 1 Pharmacokinetic parameters of flupirtine (5 mg/kg) after IV and PO administrations in 434 
healthy cats (n = 6) 435 
  Route Parameters Units 
  IV PO 
AUC h*ng/mL 77299 ± 14908 27856 ± 9719 
Cmax ng/mL / 2460 ± 453 
Tmax h / 2.78 ± 0.77 
K01 1/h / 1.66 ± 1.11 
K10 1/h 0.36 ± 0.11 0.12 ± 0.03 
K12 1/h 1.64 ± 1.09 0.07 ± 0.13 
K21 1/h 0.41 ± 0.15 0.20 ± 0.17 
K01_HL h / 1.57 ± 0.38 
K10_HL h 2.32 ± 0.99 3.42 ± 1.38 
Alpha 1/h 2.13 ± 1.07 0.41 ± 0.19 
Beta 1/h 0.063 ± 0.015 0.044 ± 0.023 
Alpha_HL h 0.42 ± 0.25 3.09 ± 1.94 
Beta_HL h 11.31 ± 2.24 13.67 ± 4.43 
A ng/mL 22314 ± 10632 / 
B ng/mL 4292 ± 1447 / 
CL mL/h/kg 45.09 ± 28.01 195.0 ± 55.04 
V2 mL/kg 467.1 ± 463.5 1798 ± 845 
F%  / 39.3 ± 9.7 
 436 
AUC, area under the plasma concentration–time curve; Cmax, peak plasma concentration; Tmax, time of peak; K01, 437 
absorption rate; K10, elimination rate from compartment 1; K12, rate of movement from compartment 1 to 2; K21, rate 438 
of movement from compartment 2 to 1; K01_HL, half-life of the absorption phase; K10_HL, half-life of the elimination 439 
phase; Alpha_HL, distribution half-life; Beta_HL, elimination half-life; Alpha, rate constant associated with 440 
distribution; Beta, rate constant associated with elimination; A, intercept for the distribution phase; B, intercept for the 441 
elimination phase; CL, clearance; V1, volume of compartment 1; V2, volume of compartment 2; F%, bioavailability. 442 
 443 
 444 
445 
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Legends to figures 446 
Fig. 1. Molecular structure of flupirtine 447 
 448 
Fig. 2. Mean semi logarithm plasma concentrations of flupirtine vs. time curves following PO 449 
(─●─) and IV (--○--) administrations of flupirtine (5  mg⁄∕kg)  in healthy cats (n = 6). Bars represent 450 
the standard deviations. 451 
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